CTLA-4 Blockade Bioassay
Measure Potency and Stability of Biologics Designed to Block CTLA-4 Interactions
- Prequalified according to ICH guidelines
- 96- and 384-well plate formats
- No primary cell culture required
- Supplied in convenient thaw-and-use format; also available in cell propagation model (CPM) format
Catalog Number:
Choose a Product
Size
Catalog Number: JA3001
Catalog Number: JA3005
Catalog Number: JA1400
Catalog Number: JA1020
Measure the ability of biologics to block immune checkpoint signals
CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4), also known as CD152, is an immune inhibitory receptor constitutively expressed on regulatory T cells (Tregs) and upregulated in activated T cells. CTLA-4 plays a critical role in regulating immune responses to tumor antigens and autoantigens. When CTLA-4 expression is upregulated on the surface of T cells, the T cells bind B7 with a higher avidity, and thus outcompete the positive co-stimulatory signal from CD28. In addition, engagement of CTLA-4 by either of its ligands, CD80 (B7-1) or CD86 (B7-2) on an adjacent antigen presenting cell (APC) inhibits CD28 co-stimulation of T cell activation, cell proliferation and cytokine production.
The CTLA-4 Blockade Bioassay reflects the mechanism of action (MOA) of biologics designed to block the interaction of CTLA-4 with its ligands, CD80 and CD86.
Control Ab, Anti-CTLA-4, is a blocking antibody that shows blocking activity of CTLA-4 with its ligands CD80 and CD86. It is intended for use as a control with the CTLA-4 Blockade Bioassay, which can be used to measure the potency and stability of antibodies and other biologics designed to block the CTLA-4/CD80 and CD86 interaction.
Assay Components
The assay consists of two genetically engineered cell lines:
CTLA-4 Effector Cells: Jurkat T cells stably expressing human CTLA-4 and a luciferase reporter driven by a native promoter which responds to TCR/CD28 activation
aAPC/Raji Cells: Raji cells expressing an engineered cell surface protein designed to activate cognate TCRs in an antigen-independent manner and endogenously expressing CTLA-4 ligands CD80 and CD86
When the two cell types are co-cultured, CTLA-4 competes with CD28 for their shared ligands, CD80 and CD86, and thus inhibits CD28 pathway activation and promoter-mediated luminescence. Addition of an anti-CTLA-4 antibody blocks the interaction of CTLA-4 with its ligands CD80 and CD86 and results in promoter-mediated luminescence.
The CTLA-4 Blockade Bioassay is also available in CPM format, containing cryopreserved cells that can be thawed, propagated and banked for long-term use.
The Workflow
Traditional Method
'Cells as reagents' Method
Standardized Reagents Improve Results
- Thaw-and-use cell format provides significant time and labor savings over traditional methods while reducing variability.
- Kit includes all of the required reagents in standardized formats.
- Easily amenable to high-throughput workflows.
The Assay Principle
The CTLA-4 Blockade Bioassay is a bioluminescent cell-based assay that overcomes the limitations of existing assays and can be used to measure the potency and stability of antibodies and other biologics targeting CTLA-4.
Representation of the CTLA-4 Blockade Bioassay. The bioassay consists of two genetically engineered cell lines, CTLA-4 Effector Cells and aAPC/Raji Cells. Panel A. When co-cultured, the CTLA-4/CD80 and CD86 interaction inhibits CD28 pathway-activated luminescence. The addition of anti-CTLA-4 antibody blocks the CTLA-4/CD80 and CD86 interaction, thereby re-establishing CD28 pathway-activated luminescence, which can be detected in a dose-dependent manner by addition of Bio-Glo™ Reagent and quantitation with a luminometer. Panel B. When co-cultured with non-CTLA-4-expressing Effector Cells (Cat.# J1631), activation also induces luminescence by activation of the CD28 pathway but in a manner independent of anti-CTLA-4 antibody.
Assay Performance Data
Accuracy and Precision are critical to bioassays and the development of biologics. The CTLA-4 Blockade Bioassay is both accurate and precise. Accuracy is a measure of how close results are to a target or reference value. Precision is a measure of repeatability. This assay was developed and prequalified according to ICH guidelines for accuracy and precision, giving it the performance characteristics required for many applications of a bioassay used for antibody drug discovery research and development.
Accuracy: Measure of ability to replicate a reference or "target" value.
IntraLab Precision: Measure of repeatability from multiple assays of the same homogeneous sample under the same operating conditions over a short time (same analyst; same lab; same day).
Intermediate Precision: Measure of repeatability of multiple assays of the same homogeneous sample with different analysts or equipment or on different days.
Linearity: Ability of the assay to provide measured values that are proportional to the concentration of the sample.
The CTLA-4 Blockade Bioassay Shows Precision, Accuracy and Linearity.
| Parameter | Results | |
|---|---|---|
| Accuracy | % Expected Relative Potency | % Recovery |
| 50 | 105.3 | |
| 70 | 96.7 | |
| 130 | 108.4 | |
| 150 | 112.3 | |
| Repeatability (% CV) | 100% (Reference) | 6.7 |
| Intermediate Precision (% CV) | 10.2 | |
| Linearity (r2) | 0.991 | |
| Linearity (y = mx + b) | y = 1.175x – 11.45 | |
| A 50–150% theoretical potency series of ipilimumab (CTLA-4 blocking antibody) was analyzed in triplicate in three independent experiments performed on three days by two analysts. Bio-Glo™ Reagent was added and luminescence quantified using the GloMax® Discover Detection System. Data were analyzed and relative potencies calculated after parallelism determination using JMP® software. Data were generated using thaw-and-use cells. | ||
The CTLA-4 Blockade Bioassay reflects the mechanism of action (MOA) and specificity of biologics designed to block the CTLA-4/CD80 and CD86 interaction.
The CTLA-4 Blockade Bioassay measures the inhibitory activity of clinical grade anti-CTLA-4 blocking antibodies.
CTLA-4 Effector Cells were incubated with aAPC/Raji Cells in the absence or presence of anti-CTLA-4, anti-PD-1, anti-TIGIT or anti-HER2 blocking antibodies, as indicated.
CTLA-4 Effector Cells and aAPC/Raji Cells were incubated with increasing concentrations of anti-CTLA-4 antibody, ipilimumab, for 6 hours.
Product Kit Formats and Related Products
- Thaw-and-Use format kits are available in 1X and 5X sizes.
- Cell Propagation Model format is also available (Cat.# JA1400).
- Control Ab, Anti-CTLA-4, is available separately (Cat.# JA1020).
Specifications
Catalog Number:
What's in the box?
| Item | Part # | Size |
|---|---|---|
CTLA-4 Effector Cells |
J158A | 1 × 0.8ml |
aAPC/Raji Cells |
J159A | 1 × 0.8ml |
Fetal Bovine Serum |
J121A | 1 × 4ml |
RPMI 1640 Medium |
G708A | 1 × 36ml |
Bio-Glo™ Luciferase Assay Buffer |
G719A | 1 × 10ml |
Bio-Glo™ Luciferase Assay Substrate |
G720A | 1 × 1 vial |
SDS
Search for SDSCertificate of Analysis
Use Restrictions
Not For Medical Diagnostic Use.Storage Conditions
Please see the Protocol for detailed storage conditions.
NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.
This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) discovery, development and monitoring of biologic drugs and vaccines, (3) quality assurance testing of biologic drugs and vaccines, and (4) product release assays for biologic drugs and vaccines. No other commercial use is allowed. "Commercial use” means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to propagate, modify, derivatize, genetically engineer or otherwise create variations of the cells or genes stably transfected within the cells. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all luminescence assays using this product or contact Promega to obtain a license for use of this product with reagents other than Promega’s. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.
Licensed from Lonza Cologne GmbH under U.S. Pat. Nos. 7,700,357, 8,192,990 and 8,003,389, European Pat. Nos. 1297119, 1522587, 1607484 and 1741778 and other pending and issued patents.
What's in the box?
| Item | Part # | Size |
|---|---|---|
CTLA-4 Effector Cells |
J158A | 5 × 0.8ml |
aAPC/Raji Cells |
J159A | 5 × 0.8ml |
Fetal Bovine Serum |
J121A | 5 × 4ml |
RPMI 1640 Medium |
G708A | 5 × 36ml |
Bio-Glo™ Luciferase Assay Buffer |
G719A | 5 × 10ml |
Bio-Glo™ Luciferase Assay Substrate |
G720A | 5 × 1 vial |
SDS
Search for SDSCertificate of Analysis
Use Restrictions
Not For Medical Diagnostic Use.Storage Conditions
Please see the Protocol for detailed storage conditions.
NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.
This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) discovery, development and monitoring of biologic drugs and vaccines, (3) quality assurance testing of biologic drugs and vaccines, and (4) product release assays for biologic drugs and vaccines. No other commercial use is allowed. "Commercial use” means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to propagate, modify, derivatize, genetically engineer or otherwise create variations of the cells or genes stably transfected within the cells. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all luminescence assays using this product or contact Promega to obtain a license for use of this product with reagents other than Promega’s. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.
Licensed from Lonza Cologne GmbH under U.S. Pat. Nos. 7,700,357, 8,192,990 and 8,003,389, European Pat. Nos. 1297119, 1522587, 1607484 and 1741778 and other pending and issued patents.
What's in the box?
| Item | Part # | Size |
|---|---|---|
CTLA-4 Effector Cells (CPM) |
J146A | 2 × 1ml |
aAPC/Raji Cells (CPM) |
J148A | 2 × 1ml |
SDS
Search for SDSCertificate of Analysis
Use Restrictions
Not For Medical Diagnostic Use.Storage Conditions
Please see the Protocol for detailed storage conditions.
NOT FOR MEDICAL DIAGNOSTIC USE. FOR IN VITRO USE ONLY. BY USE OF THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF THIS LIMITED USE STATEMENT. If the recipient is not willing to accept the conditions of this limited use statement, and the product is unused, Promega will accept return of the unused product and provide the recipient with a full refund.
This product may not be further sold or transferred by the recipient and may be used only by the recipient, and then only for (1) research use, (2) discovery, development and monitoring of biologic drugs and vaccines, (3) quality assurance testing of biologic drugs and vaccines, and (4) product release assays for biologic drugs and vaccines. No other commercial use is allowed. "Commercial use" means any and all uses of this product by recipient for monetary or other consideration, including providing a service, information or data to unaffiliated third parties, and resale of this product for any use. Recipient has no right to modify, derivatize, genetically engineer or otherwise create variations of the cells or genes stably transfected within the cells except that recipient may propagate and store the cells for long-term use. In addition, recipient must use Bio-Glo™ Luciferase Assay System purchased from Promega Corporation for all luminescence assays using this product or contact Promega to obtain a license for use of this product with reagents other than Promega's. PROMEGA MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE WITH REGARDS TO THIS PRODUCT. The terms of this agreement shall be governed under the laws of the State of Wisconsin, USA.
Licensed from Lonza Cologne GmbH under U.S. Pat. Nos. 7,700,357, 8,192,990 and 8,003,389, European Pat. Nos. 1297119, 1522587, 1607484 and 1741778 and other pending and issued patents.
What's in the box?
| Item | Part # | Size | Concentration |
|---|---|---|---|
Control Ab, Anti-CTLA-4 |
JA102A | 1 × 100μg | 1mg/ml |
SDS
Search for SDSCertificate of Analysis
Use Restrictions
Not For Medical Diagnostic Use.Storage Conditions
Please see the Protocol for detailed storage conditions.
Related Products
Similar Products
T Cell Activation Bioassay (NFAT/IL-2)
Choose NFAT or IL-2 kit to assess activity of biologics designed to bind and activate T cells via engagement of TCR/CD3.
J1621, J1625, J1601, J1651, J1655, J1631
PD-1/PD-L1 Blockade Bioassay
Measure the ability of biologics to block immune checkpoint signals
J1250, J1255, J1252, J1191, J1195, J1201
ADCC Reporter Bioassay, V Variant
Measure potency and stability of antibodies mediating ADCC through the high-affinity human FcγRIIIa-V receptor.
G7015, G7010, G7016, G7018, G7102, GA1130
Mouse FcγRIV ADCC Bioassay
Characterize the Fc effector activity of antibodies that bind and activate the mouse mFcγRIV receptor.
M1201, M1211, M1215, M1212
Frequently Used With
Bio-Gloâ„¢ Luciferase Assay System
Bioluminescent detection reagent qualified for use with bioassays that utilize firefly luciferase.
G7940, G7941
GloMax® Discover System
High-performance microplate reader for detecting luminescence, fluorescence and absorbance.
GM3000
RealTime-Gloâ„¢ MT Cell Viability Assay
A bioluminescent method to kinetically monitor viability in cell culture up to 72 hours.
G9711, G9712, G9713
CellTiter-Glo® 2.0 Cell Viability Assay
Updated CellTiter-Glo® Cell Viability Assay with improved reagent stability. Quantifies cell proliferation based on ATP detection.
G9241, G9242, G9243
